All In Biotech

Drug Trial Radar · NCT03621670

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,196 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,196

Actual

Start

Jul 27, 2018

Primary completion

Dec 27, 2024

Study completion Dec 27, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 6 weeks, up to 12 weeks
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccinesv(RIV).

Conditions

  • Infections, Meningococcal

Interventions

  • Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)Biological

    Bexsero was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.

  • Prevnar13Biological

    Prevnar13 (PCV13) was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.

  • PediarixBiological

    Pediarix (DTPa-HBV-IPV) was administered intramuscularly on Day 1, Day 61, and Day 121.

  • HiberixBiological

    Hiberix (Hib) was administered intramuscularly on Day 1, Day 61, and Day 121.

  • RotarixBiological

    Rotarix (HRV) was administered intramuscularly on Day 1 and Day 61.

  • M-M-R IIBiological

    M-M-R II (MMR) was administered intramuscularly on Day 301.

  • VarivaxBiological

    Varivax (VV) was administered intramuscularly on Day 301.

  • Placebo (saline water)Biological

    Placebo was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.

  • Prevnar 20Biological

    Prevnar 20 (PCV13) was administered intramuscularly as a booster dose on Day 301 group who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Any Solicited Administration Site Events After the First Vaccination Administered at Day 1Time frame: Day 1 to Day 7
  2. Number of Participants Reporting Any Solicited Systemic Events After the First Vaccination Administered at Day 1Time frame: Day 1 to Day 7
  3. Number of Participants Reporting Any Solicited Administration Site Events After the Second Vaccination Administered at Day 61Time frame: Day 61 to Day 67
  4. Number of Participants Reporting Any Solicited Systemic Events After the Second Vaccination Administered at Day 61Time frame: Day 61 to Day 67
  5. Number of Participants Reporting Any Solicited Administration Site Events After the Third Vaccination Administered at Day 121Time frame: Day 121 to Day 127
  6. Number of Participants Reporting Any Solicited Systemic Events After the Third Vaccination Administered at Day 121Time frame: Day 121 to Day 127
  7. Number of Participants Reporting Any Solicited Administration Site Events After the Fourth Vaccination Administered at Day 301Time frame: Day 301 to Day 307
  8. Number of Participants Reporting Any Solicited Systemic Events After the Fourth Vaccination Administered at Day 301Time frame: Day 301 to Day 307
  9. Number of Participants With Any Solicited Systemic AEs During the 30 Days After the Fourth Vaccination at Day 301Time frame: Day 301 to Day 330
  10. Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After the First Vaccination Administered at Day 1Time frame: Day 1 to Day 30
  11. Number of Participants Reporting Any Unsolicited AEs After the Second Vaccination Administered at Day 61Time frame: Day 61 to Day 90
  12. Number of Participants Reporting Any Unsolicted AEs After the Third Vaccination Administered at Day 121Time frame: Day 121 to Day 150
  13. Number of Participants Reporting Any Unsolicited AEs After the Fourth Vaccination Administered at Day 301Time frame: Day 301 to Day 330
  14. Number of Participants Reporting Any SAEs, AEs Leading to Withdrawal, AESIs and MAAEsTime frame: Day 1 up to study end (Day 481 for participants who have not reached 6-month follow-up at the time of Protocol Amendment 7; Day 661 for all others)
  15. Percentage of Participants With Human Serum Bactericidal Assay (hSBA) Antibody Titers >= Lower Limit of Quantitation (LLOQ) for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4) and M13520 (NHBA)Time frame: At Day 151 (1 month after the third vaccination)
  16. Percentage of Participants With hSBA Titers >= LLOQ Against All Serogroup B Test Strains Combined (Composite Response)Time frame: At Day 151 (1 month after the third vaccination)
  17. Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA) and >= 16 for Strain 96217Time frame: At Day 331 (1 month after the fourth vaccination)
  18. Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp), NZ98/254 (PorA P1.4), and M13520 (NHBA) and >= 16 for Strain 96217 (NadA) (Composite Response Across All Strains)Time frame: At Day 331 (1 month after the fourth vaccination)
  19. Adjusted Geometric Mean Concentrations (GMCs) of Immunoglobubin (IgG) Antibodies Against 13 PCV13 Antigens at 1 Month After Third VaccinationTime frame: At Day 151 (1 month after the third vaccination)

Locations

57 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Fayetteville, Arkansas

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Oakland, California

  • GSK Investigational Site

    Roseville, California

  • GSK Investigational Site

    Walnut Creek, California

  • GSK Investigational Site

    West Covina, California

  • GSK Investigational Site

    Lake Mary, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Nampa, Idaho

  • GSK Investigational Site

    Nampa, Idaho

  • GSK Investigational Site

    Newton, Kansas

  • GSK Investigational Site

    Topeka, Kansas

  • GSK Investigational Site

    Bardstown, Kentucky

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Fall River, Massachusetts

  • GSK Investigational Site

    Bingham Farms, Michigan

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    Lincoln, Nebraska

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Liverpool, New York

  • GSK Investigational Site

    Syracuse, New York

  • GSK Investigational Site

    Boone, North Carolina

  • GSK Investigational Site

    Raleigh, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Dayton, Ohio

  • GSK Investigational Site

    Dayton, Ohio

  • GSK Investigational Site

    Fairfield, Ohio

  • GSK Investigational Site

    South Euclid, Ohio

  • GSK Investigational Site

    Hermitage, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Charleston, South Carolina

  • GSK Investigational Site

    Sioux Falls, South Dakota

  • GSK Investigational Site

    Clarksville, Tennessee

  • GSK Investigational Site

    Kingsport, Tennessee

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.